

On April 22, 2018, the Board of Directors (the “Board”) of Eleven Biotherapeutics, Inc. (the “Company”) amended the Company’s Code of Business Conduct and Ethics (the “Amended Code”). The Amended Code contains updated provisions addressing conflicts of interest, which provisions now accurately reflect the Company’s status as a biologics oncology company focused primarily on designing, engineering and developing targeted protein therapeutics following the Company’s acquisition of Viventia Bio Inc. The Amended Code also clarifies the reporting procedures and certain provisions related to compliance. The Amended Code was effective upon approval by the Board and did not result in any waiver, explicit or implicit, of any provision of the Company’s previous Code of Business Conduct and Ethics.

The Amended Code is available on the Company’s website at www.elevenbio.com under the “Investors & Media – Corporate Governance” section.